Media coverage about Evoke Pharma (NASDAQ:EVOK) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Evoke Pharma earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 45.8263435531057 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Evoke Pharma (NASDAQ EVOK) opened at $2.62 on Friday. Evoke Pharma has a fifty-two week low of $2.16 and a fifty-two week high of $4.55. The stock has a market cap of $40.38, a PE ratio of -2.79 and a beta of 1.09.
Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.13). During the same quarter in the previous year, the firm posted ($0.29) earnings per share. research analysts forecast that Evoke Pharma will post -1 earnings per share for the current fiscal year.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.